(Q37845853)

24 August 2017

1 reference

title

Treatment of infection caused by Borrelia burgdorferi sensu lato (English)

1 reference

24 August 2017

0 references

0 references

1

Gary P Wormser

1 reference

24 August 2017

Susan O'Connell

2

1 reference

24 August 2017

1 February 2011

1 reference

Expert Review of Anti-infective Therapy

24 August 2017

1 reference

24 August 2017

9

1 reference

24 August 2017

2

1 reference

24 August 2017

245-260

1 reference

A Critical Appraisal of “Chronic Lyme Disease”

24 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Does this patient have erythema migrans?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Evidence-based guidelines for the management of Lyme disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Erythromycin resistance in Borrelia burgdorferi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Ineffectiveness of tigecycline against persistent Borrelia burgdorferi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Failure of treatment with cephalexin for Lyme disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

An RND-type efflux system in Borrelia burgdorferi is involved in virulence and resistance to antimicrobial compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Duration of antibiotic treatment in disseminated Lyme borreliosis: a double-blind, randomized, placebo-controlled, multicenter clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Remaining complaints 1 year after treatment for acute Lyme neuroborreliosis; frequency, pattern and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Practice Parameter: Treatment of nervous system Lyme disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Coinfections Acquired from Ixodes Ticks

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Antibiotic treatment duration and long-term outcomes of patients with early lyme disease from a lyme disease-hyperendemic area

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

A comparison of two treatment regimens of ceftriaxone in late Lyme disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Outcomes of children treated for Lyme arthritis: results of a large pediatric cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Subjective symptoms after treatment of early Lyme disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Two Controlled Trials of Antibiotic Treatment in Patients with Persistent Symptoms and a History of Lyme Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Cognitive function in post-treatment Lyme disease: do additional antibiotics help?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Role of psychiatric comorbidity in chronic Lyme disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Psychiatric comorbidity and other psychological factors in patients with "chronic Lyme disease".

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Lyme Disease Associated with Fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Long-term Outcomes of Persons With Lyme Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Lyme neuroborreliosis in children: a prospective study of clinical features, prognosis, and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Antibiotic treatment of animals infected with Borrelia burgdorferi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Detection of attenuated, noninfectious spirochetes in Borrelia burgdorferi-infected mice after antibiotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Peridomestic Lyme disease prevention: results of a population-based case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Transmission dynamics of Borrelia burgdorferi s.s. during the key third day of feeding by nymphal Ixodes scapularis (Acari: Ixodidae).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Efficacy of antibiotic prophylaxis for the prevention of Lyme disease: an updated systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Postexposure treatment with doxycycline for the prevention of tick-borne relapsing fever.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Pharmacodynamics of doxycycline for chemoprophylaxis of Lyme disease: preliminary findings and possible implications for other antimicrobials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Sustained-release formulation of doxycycline hyclate for prophylaxis of tick bite infection in a murine model of Lyme borreliosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

A sustained-release formulation of doxycycline hyclate (Atridox) prevents simultaneous infection of Anaplasma phagocytophilum and Borrelia burgdorferi transmitted by tick bite.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Final report of the Lyme disease review panel of the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Persistence of Borrelia burgdorferi following antibiotic treatment in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Genomic sequence of a Lyme disease spirochaete, Borrelia burgdorferi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

Lyme borreliosis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.10.174

21 January 2018

Identifiers

DOI

10.1586/ERI.10.174

1 reference

24 August 2017

1 reference

PubMed ID

21342072